Literature DB >> 16621365

Investigation of factors responsible for low oral bioavailability of cefpodoxime proxetil.

Vasu Kumar Kakumanu1, Vinod Arora, Arvind K Bansal.   

Abstract

Learning about the behavior of a drug in biological environment enables application of better formulation strategies to improve bioavailability of the same. Cefpodoxime proxetil (CP) is a prodrug, which is orally administered cephalosporin with only 50% absolute bioavailability. Despite previous studies, reasons responsible for low bioavailability of CP remain poorly understood. The present study tries to ascertain reasons for the low oral bioavailability of CP. The in vitro, in situ and ex vivo studies showed interesting results, where metabolism of CP into cefpodoxime acid (CA) inside the intestinal epithelial cell and preferential efflux of CA into lumen was identified as primary reason for low oral bioavailability of CP. Presence of specific carriers or transportation mechanism on the apical side membrane of enterocyte, than basal side of the same was observed.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16621365     DOI: 10.1016/j.ijpharm.2006.03.004

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  5 in total

1.  Enhancement of bioavailability of cefpodoxime proxetil using different polymeric microparticles.

Authors:  Fahim Khan; Rajesh Katara; Suman Ramteke
Journal:  AAPS PharmSciTech       Date:  2010-09-04       Impact factor: 3.246

2.  Evidence of Failure of Oral Third-Generation Cephalosporin Treatment for Shigella sonnei Infection.

Authors:  Jennifer P Collins; Cindy R Friedman; Meseret G Birhane; Beth E Karp; Anthony Osinski; Mary W Montgomery; Deepam Thomas; Jonathan Barkley; Martha C Sanchez; Samir Hanna; Azizat A Adediran; Jessica C Chen; Hayat Caidi; Louise Francois Watkins
Journal:  Open Forum Infect Dis       Date:  2020-04-18       Impact factor: 3.835

3.  Formulation and in vitro characterization of cefpodoxime proxetil gastroretentive microballoons.

Authors:  Ak Sharma; Rk Keservani; Sc Dadarwal; Yl Choudhary; S Ramteke
Journal:  Daru       Date:  2011       Impact factor: 3.117

4.  Rapamycin nanoparticles improves drug bioavailability in PLAM treatment by interstitial injection.

Authors:  Yahong Shi; Chuqiao Jiao; Xi Lu; Yifeng Nie; Xiang Li; Dong Han
Journal:  Orphanet J Rare Dis       Date:  2022-09-09       Impact factor: 4.303

5.  Oral Antibiotics in Clinical Development for Community-Acquired Urinary Tract Infections.

Authors:  Balaji Veeraraghavan; Yamuna Devi Bakthavatchalam; Rani Diana Sahni
Journal:  Infect Dis Ther       Date:  2021-08-06
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.